Recent US efforts to introduce Most Favored Nation (MFN) drug pricing are creating new layers of uncertainty for transactions involving the commercialization of prescription medicines in the US. These policies – designed to align US drug prices with the lowest prices available in comparable countries – have the potential to reshape deal economics, launch strategies, and global pricing structures. This article outlines the current MFN policy landscape and explores how these developments may affect both…